Synriam

Synriam (developed by Ranbaxy Laboratories, now part of Sun Pharma) is a fixed-dose synthetic antimalarial combination therapy containing two active pharmaceutical ingredients: arterolane maleate (formerly known as RBx11160) and piperaquine phosphate.

• Arterolane Maleate: A fully synthetic trioxolane derivative (a non-artemisinin endoperoxide). Like artemisinins, its peroxide bridge undergoes iron-dependent cleavage within the malaria parasite, generating short-lived free radicals that rapidly destroy parasitic proteins and membranes, resulting in swift blood-stage parasite clearance and fast fever relief.

• Piperaquine Phosphate: A long-acting lipophilic bisquinoline antimalarial derivative. It accumulates within the food vacuole of the parasite and inhibits the polymerization of toxic free heme into inert hemozoin. The accumulation of toxic heme causes parasitic cell destruction, clearing residual parasites and preventing disease recrudescence.

Because arterolane is completely synthetic, Synriam is independent of natural plant harvests (Artemisia annua), providing a consistent supply chain while delivering rapid parasitic clearance comparable to artemisinin-based combination therapies (ACTs).

Primary Medical Indications

Synriam is indicated for adult and pediatric populations (weighing 5 kg or more) for the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Multi-Drug Resistant Malaria: Effective against P. falciparum strains that exhibit resistance to older conventional antimalarial monotherapies (such as chloroquine, mefloquine, or sulfadoxine-pyrimethamine).

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax (radical cure for liver hypnozoites in P. vivax requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Avoid High-Fat Meals: Unlike lumefantrine-based antimalarials, piperaquine bioavailability increases substantially when co-administered with dietary fats, which can lead to elevated plasma drug levels and an increased risk of cardiac adverse effects.

• QTc Prolongation Warning: Piperaquine has the potential to prolong the QTc interval on an ECG. Avoid co-administration with other QT-prolonging agents (e.g., macrolides, antiarrhythmics, quinine, halofantrine) or in patients with uncorrected electrolyte imbalances or congenital long QT syndrome.

• Re-Dosing Protocol for Vomiting: If vomiting occurs within 1 hour of taking a dose, re-administer a full replacement dose immediately. If persistent vomiting prevents oral intake, transition the patient to parenteral therapy (e.g., IV artesunate).

• Not for Severe/Complicated Malaria: Contraindicated as monotherapy for severe or complicated malaria (e.g., cerebral malaria, severe malarial anemia, pulmonary edema). Severe cases require immediate emergency hospital admission and intravenous antimalarials.

• Prophylaxis Restriction: Synriam is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.